| Document |
Document Title |
|
WO/2012/060120 |
The purpose of the present invention is to provide a novel protein that shows specific localization in fat droplets. The present invention provides: (A) a protein in which the N-terminus of a polypeptide (b), which comprises the amino ac...
|
|
WO/2012/059593 |
The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2ΑΡ) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore...
|
|
WO/2012/059592 |
The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AR) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore p...
|
|
WO/2012/056683 |
A method for producing cAMP using a chimeric olfactory receptor comprises the following steps: (a) a step for preparing a reaction system provided with a first layer, a lipid bilayer membrane, and a second layer, the lipid bilayer being ...
|
|
WO/2012/058588 |
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are furthe...
|
|
WO/2012/055083 |
Provided is an anti-angiogenic fusion protein, which comprises a vascular endothelial cell growth inhibitor (VEGI) or variant thereof, and other polypeptide such as IgG Fc. The fusion protein optionally comprises a linker. The fusion pro...
|
|
WO/2012/056603 |
A chimeric olfactory receptor derived from a mouse-derived eugenol odorant receptor (mOREG) comprising the amino acid sequence (N-terminus)-EC1-TM1-IC1-TM2-EC2-TM3-IC2-TM4-EC3-TM5-IC3-TM6
-EC4-TM7-IC4-(C-terminus), wherein the N-terminal...
|
|
WO/2012/058363 |
The present invention provides a recombinant HIV Env antigenic protein, a virus-like particle and a recombinant HIV virus. The present invention further provides a vaccine comprising the recombinant HIV Env antigenic protein, the virus-l...
|
|
WO/2012/053828 |
The present invention relates to a fusion protein resulting from the coupling of a human interleukin-1 receptor antagonist and hybrid Fc. More specifically, provided is a fusion protein in which a human interleukin-1 receptor antagonist ...
|
|
WO/2012/053823 |
The present invention relates to a fusion protein containing blood coagulation factor IX (FIX) and transferrin. The fusion protein of the present invention has more specific activity than natural FIX, and therefore may be useful in a tre...
|
|
WO/2012/054008 |
Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maint...
|
|
WO/2012/054580 |
A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) ty...
|
|
WO/2012/050921 |
The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 310-321 of ND2. Peptides including, overlapping or from within this ...
|
|
WO/2012/048653 |
Provided in the present application is a recombinant long-life interferon fusion protein and use thereof, wherein the fusion protein consists of an N-terminal interferon and a C-terminal human albumin binding peptide as well as a glycine...
|
|
WO/2012/050402 |
The present invention relates to: a recombinant parkin protein having cell-permeable properties, wherein a macromolecule transduction domain (MTD) is fused to a degenerative-brain-disease therapeutic protein parkin; and a pharmaceutical ...
|
|
WO/2012/050374 |
Provided are chimeric antigen receptors specific to tumor associated antigens and methods of expressing such chimeric antigen receptors in activated killer cells. Also provided are methods and compositions for treating cancer using the c...
|
|
WO/2012/050919 |
Disclosed are transgenic silkworms engineered to posses and express a chimeric spider silk protein gene, the chimeric spider silk protein gene encoding a chimeric spider silk protein having spider silk domains specific for a spider silk ...
|
|
WO/2012/051247 |
Observations regarding the role of MUC1 in promoting the nuclear accumulation of EGFR led us to propose the development of peptides to block nuclear accumulation of EGFR as a means to block breast cancer progression. One exemplary peptid...
|
|
WO/2012/048430 |
An affinity-conjugated nucleoprotein-PapMV virus-like particle (ANP) system is provided. The ANP system comprises a virus-like particle (VLP) derived from the coat protein of PapMV which has been modified by the addition of one or more "...
|
|
WO/2012/049328 |
The invention relates to the design of trimeric polypeptide complexes using polypeptide structural elements derived from the collagen XVIII protein, and their use in diagnostic and therapeutic systems in vivo and in vitro. The invention ...
|
|
WO/2012/050714 |
The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenes...
|
|
WO/2012/043397 |
The present invention relates to: a peptide which is capable of binding to an immunoglobulin; and a fusion protein which comprises the peptide. The present invention also relates to a pharmaceutical composition or the like for the treatm...
|
|
WO/2012/037779 |
Disclosed are a fusion protein SAmB, a coding gene and an application thereof. The fusion protein provided in the present invention is named SAmB, comprising on the N-terminal a Shiga toxin type-II A subunit mutant protein, and on the C-...
|
|
WO/2012/040323 |
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional...
|
|
WO/2012/037687 |
The present invention relates to therapeutic polypeptides having therapeutic activity. In particular, these polypeptides are useful in the treatment of cancer or diseases associated with particular cell types, organs, or tissues, includi...
|
|
WO/2012/037288 |
The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into hydrocarbons, e.g., n-alkanes and n-alkenes, wherein ...
|
|
WO/2012/037285 |
This disclosure pertains to the functional localization of heterologous integral plasma membrane proteins (HIPMPs) lacking cleavable signal sequences into the plasma membrane (PM) of cyanobacterial hosts, e.g., JCC138 (Synechococcus sp. ...
|
|
WO/2012/037288 |
The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into hydrocarbons, e.g., n-alkanes and n-alkenes, wherein ...
|
|
WO/2012/037397 |
A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). ...
|
|
WO/2012/033382 |
The present invention relates to a novel RNA-binding protein, to a composition comprising same for detecting microRNA, and to a label-free detection method for detecting microRNA using same. According to the present invention, the method...
|
|
WO/2012/033268 |
The present invention relates to a peptide having the ability to regenerate bone tissue and for binding to apatite, and more particularly, to a peptide having the ability to regenerate bone tissue, and to a composition containing the pep...
|
|
WO/2012/034025 |
Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 an...
|
|
WO/2012/031258 |
Disclosed herein are stable complexes including an MHC class I or MHC class II recombinant T cell receptor ligand RTL polypeptide covalently linked to an antigenic determinant by a disulfide bond. Also disclosed are methods of making suc...
|
|
WO/2012/027850 |
Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in C. jejuni. The GlycoTag peptide can be in a purified and isolated form following exp...
|
|
WO/2012/030735 |
Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a family C G-protein coupled receptor (GPCR), wherein the first portio...
|
|
WO/2012/023838 |
The present invention relates to a fusion protein having a domain for regulating the transcription-activation of a transcription factor and a protein transduction domain, to a transcription factor function inhibitor comprising the same, ...
|
|
WO/2012/023580 |
The purpose of the present invention is to provide a method for highly efficiently producing low immunogenic streptavidin having an antibody bonded thereto and being in an active state. Provided is a method for producing a conjugate cons...
|
|
WO/2012/024558 |
The present invention relates to photoactivatable rapamycin compounds. The invention further relates to the use of photoactivatable rapamycin compounds to regulate the dimerization and/or activity of polypeptides in a light dependent man...
|
|
WO/2012/023579 |
The purpose of the present invention is to provide a process for producing streptavidin and a streptavidin variant having reduced immunogenicity, which can purify streptavidin and the streptavidin variant with high purity. The present in...
|
|
WO/2012/023290 |
The present invention is based on the finding that RASEF genes are overexpressed in cancer, and involved in cancer cell survival. The present invention is also based on the finding that RASEF interacts with ERK1/2. The present invention ...
|
|
WO/2012/022495 |
The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles ...
|
|
WO/2012/021512 |
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptide...
|
|
WO/2012/020871 |
The present invention relates to a composition for preventing or treating cervical cancer, the composition having human papillomavirus (HPV) plasmodium and immunity enhancer, and more specifically, to a fusion protein having a fusion pol...
|
|
WO/2012/019157 |
The present invention provides a new method for recombinantly expressing a protein of interest, such as the human BRCA2 protein, BLM protein, CtIP protein, or EXOI protein, by expressing the protein in the form of a fusion protein compri...
|
|
WO/2012/019157 |
The present invention provides a new method for recombinantly expressing a protein of interest, such as the human BRCA2 protein, BLM protein, CtIP protein, or EXOI protein, by expressing the protein in the form of a fusion protein compri...
|
|
WO/2012/012872 |
The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nuc...
|
|
WO/2012/015938 |
Disclosed are methods of making and using engineered FokI cleavage domain variants. Also disclosed are methods, compositions and fusion proteins containing obligate heterodimers of engineered FokI cleavage domain variants and DNA binding...
|
|
WO/2012/009648 |
The present invention relates to a novel fusion protein comprising a nitrate reductase (NR) and a truncated hemoglobin N (trHbN) domain. The fusion protein may be used for bioremediation of nitric oxide.
|
|
WO/2012/009705 |
Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and d...
|
|
WO/2012/006635 |
The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker wh...
|
